PT2648516T - Compostos de piridinona-piridinilo substituídos - Google Patents

Compostos de piridinona-piridinilo substituídos

Info

Publication number
PT2648516T
PT2648516T PT11847595T PT11847595T PT2648516T PT 2648516 T PT2648516 T PT 2648516T PT 11847595 T PT11847595 T PT 11847595T PT 11847595 T PT11847595 T PT 11847595T PT 2648516 T PT2648516 T PT 2648516T
Authority
PT
Portugal
Prior art keywords
pyridinyl compounds
substituted pyridinone
pyridinone
substituted
pyridinyl
Prior art date
Application number
PT11847595T
Other languages
English (en)
Inventor
Devadas Balekudru
B Monahan Joseph
R Selness Shaun
f schindler John
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of PT2648516T publication Critical patent/PT2648516T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
PT11847595T 2010-12-06 2011-12-06 Compostos de piridinona-piridinilo substituídos PT2648516T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42007410P 2010-12-06 2010-12-06

Publications (1)

Publication Number Publication Date
PT2648516T true PT2648516T (pt) 2018-11-29

Family

ID=46162793

Family Applications (1)

Application Number Title Priority Date Filing Date
PT11847595T PT2648516T (pt) 2010-12-06 2011-12-06 Compostos de piridinona-piridinilo substituídos

Country Status (13)

Country Link
US (3) US20120142709A1 (pt)
EP (2) EP2648516B1 (pt)
JP (1) JP5848775B2 (pt)
CN (1) CN103391718A (pt)
CA (1) CA2819889C (pt)
DK (1) DK2648516T3 (pt)
ES (2) ES2873029T3 (pt)
HR (1) HRP20181788T1 (pt)
HU (1) HUE040101T2 (pt)
PL (1) PL2648516T3 (pt)
PT (1) PT2648516T (pt)
SI (1) SI2648516T1 (pt)
WO (1) WO2012078684A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3003039T (lt) * 2013-06-07 2021-05-10 Aclaris Therapeutics, Inc. Metil/fluor-piridinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai ir fluor-pirimidinil-metoksi grupės pakeistieji piridinono-piridinilo junginiai
CN104860932B (zh) * 2015-05-13 2018-01-12 安阳师范学院 一种吡唑啉酮类化合物及其应用
CN104892499B (zh) * 2015-06-26 2017-07-21 江西省科学院应用化学研究所 一种2‑吡啶酮类衍生物的合成方法
JP7282039B2 (ja) * 2017-03-16 2023-05-26 セルジーン シーエーアール エルエルシー Mk2阻害剤、その合成、およびそれに至るまでの中間体
JP2022542434A (ja) * 2019-07-31 2022-10-03 アクラリス セラピューティクス,インコーポレイテッド 重水素化mk2経路阻害剤およびその使用方法
CA3172088A1 (en) * 2020-03-27 2021-09-30 Walter Smith Oral compositions of mk2 pathway inhibitor for treatment of immune conditions
CA3198300A1 (en) * 2020-11-23 2022-05-27 Gary A. Decrescenzo Methods of synthesizing substituted pyridinone-pyridinyl compounds
CR20230468A (es) 2021-03-31 2023-12-07 Xinthera Inc Inhibidores de mk2 y usos de estos
TW202317544A (zh) 2021-07-09 2023-05-01 美商辛瑟拉股份有限公司 吡啶酮mk2抑制劑及其用途
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
TW202315625A (zh) * 2021-08-13 2023-04-16 大陸商深圳信立泰藥業股份有限公司 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途
WO2023125707A1 (zh) * 2021-12-29 2023-07-06 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
CN116354935A (zh) * 2021-12-29 2023-06-30 上海美悦生物科技发展有限公司 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途
WO2023134765A1 (zh) * 2022-01-14 2023-07-20 上海翰森生物医药科技有限公司 含五元环类衍生物、其制备方法和应用
CN118525005A (zh) 2022-01-14 2024-08-20 上海翰森生物医药科技有限公司 含吡啶多环类衍生物、其制备方法和应用
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
WO2023217184A2 (zh) * 2022-05-12 2023-11-16 上海美悦生物科技发展有限公司 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途
WO2024022412A1 (zh) * 2022-07-28 2024-02-01 深圳信立泰药业股份有限公司 一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用
WO2024046327A1 (zh) * 2022-08-30 2024-03-07 长春金赛药业有限责任公司 p38α-MK2抑制剂化合物、药物组合物及其应用
CN118047757A (zh) * 2022-11-16 2024-05-17 上海美悦生物科技发展有限公司 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途
CN118344289A (zh) * 2023-01-13 2024-07-16 上海美悦生物科技发展有限公司 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO2000071535A1 (en) 1999-05-21 2000-11-30 Scios Inc. INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE
NZ522773A (en) * 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
JP2004529859A (ja) 2000-11-20 2004-09-30 サイオス インコーポレイテッド インドール誘導体とp38キナーゼの阻害剤としてのその使用方法
US7314752B2 (en) 2001-07-19 2008-01-01 Common Sense, Ltd. Secretion-monitoring article
MXPA04004830A (es) * 2001-11-22 2004-07-30 Ono Pharmaceutical Co Compuestos derivados de piperidin-2-ona, y composiciones farmaceuticas que los contienen como ingredientes activos.
JP4359146B2 (ja) * 2002-02-13 2009-11-04 エフ.ホフマン−ラ ロシュ アーゲー 新規なピリジン−およびピリミジン−誘導体
GEP20063937B (en) * 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
AU2003267098B2 (en) 2002-09-11 2008-11-20 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
CL2004002050A1 (es) * 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
JP2005255675A (ja) 2004-02-09 2005-09-22 Tanabe Seiyaku Co Ltd 医薬組成物
AU2005211733A1 (en) 2004-02-11 2005-08-25 Shionogi & Co., Ltd HIV integrase inhibitors
WO2005105743A1 (ja) * 2004-04-28 2005-11-10 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
CA2603959A1 (en) 2005-04-08 2006-10-19 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
TW200740755A (en) 2005-07-13 2007-11-01 Bayer Cropscience Sa Dihalogenation of N,O-disubstituted hydroxypyridones and their uses
WO2007081901A2 (en) 2006-01-05 2007-07-19 The Scripps Research Institute Pyrimidinone derivatives as protein kinase inhibitors
PE20080150A1 (es) 2006-06-02 2008-04-11 Janssen Pharmaceutica Nv Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
WO2008041090A1 (en) * 2006-10-06 2008-04-10 Pfizer Limited Malanin concentrating hormone receptor-1 antagonist pyridinones
BRPI0719060A2 (pt) 2006-11-24 2014-02-04 Takeda Pharmaceutical Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto
EP2086938B1 (en) 2006-12-07 2012-01-25 Novartis AG Organic compounds
US8198276B2 (en) 2007-06-06 2012-06-12 Xcovery Holding Company Llc Kinase inhibitor compounds
EA016595B1 (ru) 2007-07-17 2012-06-29 Бристол-Маерс Сквибб Компани Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
WO2009156484A2 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies

Also Published As

Publication number Publication date
ES2697607T3 (es) 2019-01-25
EP2648516A1 (en) 2013-10-16
ES2873029T3 (es) 2021-11-03
US20140171449A1 (en) 2014-06-19
CA2819889A1 (en) 2012-06-14
EP2648516A4 (en) 2014-04-30
HUE040101T2 (hu) 2019-02-28
WO2012078684A1 (en) 2012-06-14
PL2648516T3 (pl) 2019-04-30
US20140171450A1 (en) 2014-06-19
JP5848775B2 (ja) 2016-01-27
US9365546B2 (en) 2016-06-14
CA2819889C (en) 2020-12-15
EP3469907B1 (en) 2021-03-03
JP2013544889A (ja) 2013-12-19
US20120142709A1 (en) 2012-06-07
US9365547B2 (en) 2016-06-14
EP3469907A1 (en) 2019-04-17
DK2648516T3 (da) 2019-01-02
SI2648516T1 (sl) 2019-01-31
HRP20181788T1 (hr) 2018-12-28
EP2648516B1 (en) 2018-09-05
CN103391718A (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
HRP20181788T1 (hr) Supstituirani spojevi piridinon-piridinil
IL223783A0 (en) Pro-neurogenic compounds
GB201015949D0 (en) Compounds
GB201008134D0 (en) Compounds
HK1187908A1 (zh) 咪唑並三嗪酮化合物
AP2012006641A0 (en) New compounds
GB201020179D0 (en) New compounds
GB201007286D0 (en) New compounds
GB201007203D0 (en) Novel compounds
GB201007347D0 (en) Compounds
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
EP2649050A4 (en) LINKS
GB201002563D0 (en) Compounds
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201002216D0 (en) Compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201021494D0 (en) Compounds
GB201013507D0 (en) Compounds
GB201022042D0 (en) Compounds
GB201019227D0 (en) Compounds
GB201015757D0 (en) Compounds
GB201015145D0 (en) Compounds